Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the effects of a drug called LBH589 when given to
people with recurrent or refractory Hodgkin or Non-Hodgkin's lymphoma. The safety of this
drug will also be studied. The participants' physical state, changes in the size of the
tumor, or state of Hodgkin or non-Hodgkin's Lymphoma, and laboratory findings taken while
on-study will help the researchers decide if LBH589 is safe and effective.